The Trump administration's Justice Department is preparing to defend Biden's Inflation Reduction Act in court, supporting its controversial price controls on prescription drugs. This decision has sparked internal conflict as top health-care officials within the Biden administration caution that such price controls could stifle drug innovation, leading to fewer life-saving medications entering the market. Critics within the administration argue that the long-term impacts on health outcomes and economic costs could be severe, advocating for alternative measures to improve drug affordability without imposing strict price limits. The IRA sets phased price control implementations starting in 2026.
President Biden's Inflation Reduction Act faces criticism from within the current Justice Department, underscoring contradictions in supporting its price controls on drugs.
Health-care policymakers warn that pricing controls in the Inflation Reduction Act could hinder innovation, impacting the availability of life-saving drugs.
#inflation-reduction-act #prescription-drug-prices #drug-innovation #biden-administration #healthcare-policy
Collection
[
|
...
]